Inovio Pharmaceutical (INO) will begin human testing in April
For INO-4800, preclinical testing was performed between Jan. 23 and Feb. 29. The company plans to begin clinical trials in the U.S. with 30 participants in April. The company also plans to launch human trials in China and South Korea the same month. Inovio should have the first results in fall and has reported that it plans to have 1 million doses of the vaccine ready for additional clinical trials or emergency use by the end of the year. Inovio was reported that it had received a $5 million grant from the Bill & Melinda Foundation to develop and test a delivery device for the vaccine candidate. Keep an eye on Inovio as they have the support and show great signs of being a noticeable competitor in the race for the vaccine. With the support of the Gates family, this company could be on the verge of something truly great.